Arcturus Therapeutics Third Quarter 2026 Earnings Call - ARCTURUS THERAPEUTICS HOLDINGS INC

Financial Performance:

• Cash and cash equivalents decreased to $184.8 million as of September 30, 2026, from $230.9 million in December 2025, primarily driven by clinical development spend offset by a $12 million termination payment from CSL Securus.
• Q3 2026 revenue was $18.3 million (vs. $17.2 million YoY), while nine-month revenue was $23.3 million (vs. $74.8 million YoY); Q3 revenue increase was driven by the $12 million CSL payment and deferred revenue recognition, whereas the nine-month decline reflected the loss of prior CSL collaboration revenue and lower BARDA grants.
• R&D expenses decreased to $17 million in Q3 and $56 million for the first nine months (vs. $23.3 million and $87.7 million YoY respectively), driven by reduced clinical/manufacturing activities on lower-priority programs and lower personnel costs.
• Net loss was $7.4 million for Q3 ($0.26/share) and $58.2 million for the first nine months ($2.05/share), compared to $13.4 million and $36.7 million in the prior year periods.
• Cash runway extends over two years through year-end 2028.

Guidance and Future Outlook:

• Phase 2 dosing for ARCT2601 (Lunar 2.0 OTC program) is scheduled to begin in Q1 2027, with top-line data expected in H2 2027.
• Enrollment for ARCT032 (Cystic Fibrosis) Cohort 4 is projected to complete by year-end 2026.
• Full Phase 2 data presentation for ARCT032 is planned for Q2 2027; top-line data will be available prior to this full presentation to inform the Go/No-Go decision.
• IND submission for the Phenylketonuria (PKU) Lunar 2.0 program is targeted for H2 2027.
• Commercialization of CoastAve (mRNA COVID vaccine) is planned for 2027 in the EU/UK, while the U.S. market will be pursued via a partner.

Business Segments and Product Lines:

• Liver Therapeutics: ARCT810 (OTC deficiency) demonstrated meaningful biomarker activity (ammonia and glutamine reduction) in Phase 2; ARCT2601, utilizing the new Lunar 2.0 platform, showed a 38-fold potency improvement in non-human primates.
• Respiratory: ARCT032 (Cystic Fibrosis) is in Phase 2 evaluation for Class 1 CF subjects; enrollment accelerated in Israel and Turkey with a 10mg dose.
• Vaccines: CoastAve (self-amplifying mRNA) is commercialized in Japan; Phase 1 pandemic influenza vaccine data published in Nature Communications showed single-dose potential and immunological benefits over standard care.
• Technology: Acquired MyNeo to integrate AI-driven antigen design and neoantigen capabilities, expanding potential into oncology.
• Pipeline Expansion: Lunar 2.0 is enabling entry into new genetic diseases including PKU and gout.

Market and Competitive Landscape:

• ARCT032 targets an unmet need in Class 1 CF subjects where standard of care is limited; the program aims to utilize the CF Foundation's "REACH" natural history study for external control data to enable smaller Phase 3 trials.
• Management noted competitor Vertex's recent halt of an mRNA/LNP program due to safety concerns (requiring systemic steroids), contrasting this with ARCT032's safer profile which does not require pre-dosing with systemic steroids.
• FDA engagement has been constructive, with Type C meetings providing clarity on regulatory pathways for ARCT2601.

Risks and Challenges:

• Safety: While ARCT032 has shown a favorable safety profile to date, the open-label study design requires careful monitoring to prevent data bias, with real-time efficacy data access restricted to medical personnel.
• Clinical Validation: The critical risk remains translating the 38-fold preclinical potency gain from non-human primates to clinical efficacy in humans.
• Commercial Execution: Transitioning marketing authorization for CoastAve from CSL Securus to Arcturus in the EU/UK introduces execution risks for 2027 commercial objectives.
• Funding/Revenue Volatility: Future revenue is heavily dependent on successful partnership structures or grant renewals, as current revenue is low and non-dilutive.

Management Commentary and Tone:

• Tone is confident and focused on "disciplined execution" and capital allocation, emphasizing the strategic value of Lunar 2.0 and the AI acquisition.
• Management highlighted the "first opportunity" to validate Lunar 2.0 clinical translation with ARCT2601.
• CEO Joe Payne emphasized the company's focus remains on mRNA therapeutics rather than pivoting to a personalized oncology vaccine business, though they remain open to partnerships in that space.
• CFO Denis Mulroy expressed confidence in the balance sheet strength and the ability to reach milestones through 2028.

Analyst Questions and Answers:

• CF Data Timing: Clarified that Go/No-Go decisions will be based on top-line data available prior to the Q2 2027 full presentation; enrollment completion is still expected by year-end 2026.
• ARCT2601 Patient Population: Patients in the new study will be prioritized with elevated baseline ammonia/glutamine levels to maximize the observable delta in efficacy compared to the previous ARCT810 cohort.
• ARCT2601 Dosing: The Phase 2 study will enroll approximately six patients; this small sample size is deemed sufficient due to the 38-fold potency increase of Lunar 2.0.
• Endpoint Clarity: FDA is expected to focus on the reduction and stabilization of serum ammonia and glutamine levels, including during increased protein intake, as primary endpoints for Phase 3.
• Oncology Strategy: Confirmed that while MyNeo provides oncology capabilities, Arcturus will not become a personalized neoadjuvant vaccine company but will license technology or partner with key players.
• CoastAve Partnerships: U.S. commercialization will utilize a partner; EU/UK commercialization will be internal following the transfer of marketing authorization rights.

Other Key Points:

• ARCT2601 dosing in pediatric populations (ages 12+) aims to prevent irreversible neurological damage from ammonia spikes.
• The REACH study by the CF Foundation is expected to provide a normative dataset in H2 2027 to support potential Phase 3 regulatory negotiations.
• Self-amplifying mRNA technology is highlighted as a key differentiator for pandemic preparedness and potential future applications in oncology.